Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease

Metabolism: Clinical and Experimental

Volumn 47, Issue 6, 1998, Pages 675-680

  Hoogerbrugge, N ^a   Zillikens, M C ^a   Jansen, H ^a   Meeter, K ^a   Deckers, J W ^a   Birkenhager J C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; ESTRADIOL VALERATE; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SMOKING;

EID: 0031746347     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90029-4     Document Type: Article

References (37)

1. Grady D, Rubin SM, Petiti DB: Hormone therapy to prevent disease and prolong life in post menopausal women. Ann Intern Med 117:1016-1037, 1992
2. Belchetz PE: Hormonal treatment of postmenopausal women. N Engl J Med 330:1062-1071, 1994
3. Writing Group for the PEPI Trial: Effects of estrogen or estrogen/ progestagen regimens on heart disease risk factors in postmenopausal women. JAMA 273:199-208, 1995
4. Sack MN, Rader DJ, O Cannon R III: Oestrogen and inhibition of oxidation of low-density lipoprotein in postmenopausal women. Lancet 343:269-270, 1994
5. Tilly-Kiesi M, Lappi M, Puolakka J, et al: Different effects of continuous oestrogen-progestin and transdermal oestrogen with cyclic progestin regimens on low-density lipoprotein subclasses. Eur J Clin Invest 26:1125-1133, 1996
6. Rifici VA, Khachadurian AK: The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism 41:1110-1114, 1992
7. Chait A: Methods for assessing lipid and lipoprotein oxidation. Curr Opin Lipidol 3:389-394, 1992
8. Yla-Herttuala S, Palinski W, Rosenfield ME, et al: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989
9. Yla-Herttuala S, Palinski W, Butler S, et al: Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 14:32-40, 1994
10. Salonen JT, Ylä-Herttuala S, Yamamoto R, et al: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 339:883-887, 1992
11. Esterbauer H, Striegl G, Puhl H, et al: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6:67-75, 1989
12. de Graaf J, Hendriks JCM, Demacker PNM, et al: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 11:298-306, 1991
13. Chait A, Brazg RL, Tribble DL, et al: Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic phenotype, pattern-B. Am J Med 94:350-356, 1993
14. Campos H, McNamara JR, Wilson PWF, et al: Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal women and postmenopausal women. J Clin Endocrinol Metab 676:30-35, 1988
15. Jenssen J, Christiansen C, Rødbro P: Cigarette smoking, serum estrogen and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 313:973-975, 1985
16. Kiel DP, Baron JA, Anderson JJ, et al: Smoking eliminates the protective effect of oral estrogens on the risk for hip fracture among women. Ann Intern Med 116:716-721, 1992
17. Scheffler E, Wiest E, Woehrle J, et al: Smoking influences the atherogenic potential of low-density lipoprotein. Clin Invest 70:263-268, 1992
18. Kleinveld HA, Hak-Lemmers HLM, Stalenhoef AFH, et al: Improved measurement of low density lipoprotein susceptibility to copper induced oxidation: Application of a short procedure for LDL. Clin Chem 38:2066-2072, 1992
19. 2+/dextran sulfate in its enzymatic measurement. Clin Chem 24:931-933, 1978
20. Jansen H, Hop W, van Toi A, et al: Hepatic lipase and lipoprotein lipase are not major determinants of the low density lipoprotein subclass pattern in human subjects with coronary heart disease. Atherosclerosis 107:45-54, 1994
21. Havekes LM, de Knijf P, Beisiegel U, et al: A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 28:455-463, 1987
22. Redgrave TG, Roberts DCK, West CE: Separation of plasma lipoproteins by density gradient ultracentrifugation. Ann Biochem 65:42-49, 1975
23. Palinski W, Ylä-Herttuala S, Rosenfeld ME, et al: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325-335, 1990
24. Jansen H, Ghanem H, Kuypers JHSAM, et al: Autoantibodies against malondialdehyde-modified LDL are elevated in subjects with an LDL subclass pattern B. Atherosclerosis 115:255-262, 1995
25. Armstrong VW, Wieland E, Diedrich F, et al: Serum antibodies to oxidized low-density iipoprotein in pre-eclamptic and coronary disease. Lancet 343:1570-1571, 1994
26. Maggi E, Finrdi G, Poli M, et al: Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 4:1119-1122, 1993
27. Parums DV, Brown DL, Mitchinsin MJ: Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis. Arch Pathol Lab Med 114:383-387, 1990
28. Schumacher M, Eber B, Tatzber F, et al: LDL oxidation and coronary atherosclerosis. Lancet 340:123, 1992
29. Eber B, Schumacher M, Tatzer F, et al: Autoantibodies to oxidized low density lipoproteins in restenosis following coronary angioplasty. Cardiology 84:310-315, 1994
30. Griffin B, Farish E, Walsh D, et al: Response of plasma low density lipoprotein subfractions to oestrogen replacement following surgical menopause. Clin Endocrinol (Oxf) 39:463-468, 1993
31. Griffin BA, Packard CJ: Metabolism of VLDL and LDL subclasses. Curr Opin Lipidol 5:200-206, 1994
32. Grodstein F, Stampfer MJ, Manson JE, et al: Postmenopausal estrogen and progestagen use and risk of cardiovascular disease. N Engl J Med 335:453-461, 1996
33. Jensen J, Christiansen C: Dose-response effects on serum lipids and lipoproteins following combined oestrogen progestagen therapy in post-menopausal women. Maturitas 9:259-266, 1987
34. Bass KM, Newshaffer CJ, Klag MJ, et al: Plasma lipoprotein levels as predictors of cardiovascular death in women. Arch Intern Med 153:2209-2216, 1993
35. Michnovicz JJ, Herschpf RJ, Naganuma H, et al: Increased 2-hydroxylation of estradiol as a possible mechanism for the antiestrogenic effect of cigarette smoking. N Engl J Med 315:1305-1309, 1986
36. Lobo RA, Pickar JH, Wild RA, et al: Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstet Gynecol 84:987-995, 1994
37. Siekmeier R, Wulfroth P, Wieland H, et al: Low-density lipoprotein susceptibility to in vitro oxidation in healthy smokers and non-smokers. Clin Chem 42:524-530, 1996